Managing the Cost of C. difficile Infection with Novel Therapies: Best Practices in Managed Care for Improved Clinical and Economic Outcomes

Managing the Cost of C. difficile Infection with Novel Therapies: Best Practices in Managed Care for Improved Clinical and Economic Outcomes is organized by National Association of Managed Care Physicians (NAMCP) and will be held from Nov 01, 2021 - Nov 01, 2023.,,Description:,The epidemiology and incidence of hospital- and community-acquired Clostridium difficile infection (CDI) has changed over the past decade resulting in increased cases of initial and recurrent infection. Up to 25% of patients with an initial episode of CDI experience disease recurrence. Recurrent CDI is particularly challenging to manage.,,This webcast series will provide education on reducing the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and managed care considerations around the prevention and management of rCDI.,,A Closer Look at the Prevention and Management of C. difficile Infection and Recurrence: Expert Perspectives for Improved Clinical and Economic Outcomes:,• Examine the clinical burden of C. difficile infection, including recurrent infections,• Assess tools to identify patients who may be at increased risk for recurrent C. difficile infection,• Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations,• Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection,• Apply recent evidence-based and expert consensus strategies for closing critical gaps in C. difficile infection care transitions and coordination,• Examine the recently updated IDSA and ACG clinical guidelines for the first-line management of CDI and guideline updates for prevention of CDI recurrence,,Managing the Cost of C. difficile Infection and Recurrence with Novel Therapies: Best Practices in Managed Care for Improved Clinical and Economic Outcomes:,• Examine the economic burden of C. difficile infection, including recurrent infections,• Discuss recent efficacy and safety data on the treatment of CDI, including options to reduce recurrence,• Illustrate avoidable costs related to CDI treatment management that can impact benefit design and coverage decision-making,• Apply recent evidence-based and expert consensus strategies for closing critical gaps in C. difficile infection care transitions and coordination,• Examine the recently updated IDSA and ACG clinical guidelines and the effect of these changes on managed care professionals